Ziglim 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients whose diabetes cannot be managed adequately with diet and exercise alone. Glimepiride enhances peripheral insulin sensitivity and reduces hepatic glucose production, contributing to its antihyperglycemic effects. Ziglim 2 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. The dosage should be individualized based on the patient’s glycemic response, with careful monitoring to minimize the risk of hypoglycemia, a common adverse effect associated with sulfonylureas. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes mellitus, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Regular blood glucose monitoring and periodic assessment of renal and hepatic function are recommended during therapy. Patients should be educated on recognizing symptoms of hypoglycemia and the importance of adherence to prescribed regimens. Ziglim 2 Tablet offers an effective option for improving glycemic control in type 2 diabetes when used under medical supervision.